SBIR/STTR Research Award

OCT Imaging of Diabetic Retinopathy in 1060nm Spectral Range (- for Diagnostic Sc

Award identifier fb6759f8b8c62bc3761aabf8429762a7e2915f529e35cb3d651ab6c58a852428Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,180,910

Program and phase

SBIR · Phase II

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MICRON OPTICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The objective of the proposed SBIR Phase-II Competing Renewal under RFA-EY-09-001 is to develop inexpensive and compact ophthalmic instruments for rapid diabetic retinopathy (DR) detection and screening. To achieve the program objective, the key aims will be to [1] generate functional swept-source optical coherence tomography (F-SS-OCT) system at 1060nm spectral region to perform early detection of DR by imaging retinal layers and choroidal microvasculature at video rates, [2] to develop effective image analysis methods to speed screening, and [3] to conduct human clinical trials with the goal to extract the defining DR disease signature. The final F-SS-OCT engine will be a compact, turn-key device that can greatly facilitate integration into a system integrator's ophthalmic imaging instrument for use by primary-care physicians as well as medical professionals at easily accessible public locales and retail stores. The ultimate benefit of this work is to create an affordable and enabling technology to provide both morphological and blood flow information for the diagnosis and management of diabetic retinopathy. Supported by the combined advantages of deep light penetration, minimal tissue dispersion, higher safe light exposure, high sensitivity, resolution, and speed, the 1060nm F-SS-OCT technology should enable superior imaging for DR. Current retinal OCT systems use light sources centered at 820nm for clear intraretinal layer imaging but have insufficient penetration depth for imaging the choroidal microvasculature. The choroid plays an important role in many ocular diseases including DR. Imaging and quantifying choroidal blood flow with F-SS-OCT would provide valuable information in both diagnosing and managing these ocular diseases at earlier stages. Based on the research accomplished in the current Phase-II NEI-SBIR, this renewal program is well positioned to greatly facilitate the commercialization of functional OCT imaging system by extending beyond the current swept laser technology to encompass a fully self-contained F-SS-OCT engine. Therefore, this program will focus on advancing the novel swept laser technology, developing the OCT engine, performing functional OCT imaging tests, conducting human clinical trials, and developing and verifying image analysis methods for rapid DR screening. New product manufacturing process will also be initiated to ensure successful commercialization. PUBLIC HEALTH RELEVANCE: The objective of the program is to develop inexpensive and compact swept source optical coherence tomography engine at 1060nm spectral region for rapid diabetic retinopathy (DR) detection and screening. DR is a significant complication of diabetes and is the third leading cause of blindness in the US.; furthermore, DR remains the leading cause of new blindness in working aged people in the Western World . Generating real-time measurements of blood flow and correlating the findings with tissue morphology in normal and diseased eyes is a novel and powerful approach to understanding the disease-related abnormalities in the retina. The final engine will be a compact, turn-key device that can greatly facilitate integration into a system integrator's ophthalmic imaging instrument for use by primary-care physicians as well as medical professionals at easily accessible public locales and retail stores. The ultimate benefit of this work is to create an affordable and enabling technology to provide both morphological and blood flow information for the diagnosis and management of diabetic retinopathy.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.